Health and Me

Supriya Ramesh

Dizzy Spells Misread as Vertigo Led to Brain Tumour Diagnosis for 63-Year-Old

Credits: Canva

When 63-year-old John Starns slumped on a train station bench in Sevenoaks, drenched in sweat and struggling to stay upright, most passers-by assumed he was drunk. He looked wobbly, pale, and visibly disoriented. But what looked like an awkward case of public intoxication turned out to be something far more sinister: a brain tumour hiding behind symptoms commonly mistaken for vertigo. 

<h3>From “It’s Just Vertigo” to “You Have a Brain Tumour”</h3>Initially told he had vertigo, John tried to carry on with his life. But as the months passed, his dizziness became more intense and debilitating. At their worst, the episodes forced him to lie down, eyes shut, until the world stopped spinning. Still, no one suspected the real cause.

Three months and one MRI scan later, John finally got the truth. He reportedly had a <span>vestibular schwannoma</span>, a rare, <span>benign brain tumour</span> sitting on the nerve that connects the brain to the inner ear. It was affecting his balance, hearing, and overall coordination, symptoms that, in hindsight, were never typical of garden-variety vertigo.

<h3>What is Vestibular Schwannoma?</h3>Despite the intimidating name, a vestibular schwannoma is not cancerous. It develops slowly over time from Schwann cells, the fatty insulation on your nerves. In this case, the tumour formed on the vestibulocochlear nerve, which governs both hearing and balance.

That is why the symptoms can masquerade as something much less serious. 

<ul><li>Dizziness or vertigo</li><li>Hearing loss in one ear</li><li>Ringing or buzzing sounds (tinnitus)</li><li>Poor sound localisation</li><li>In more advanced cases, numbness on one side of the face</li></ul>

Because these tumours grow at a glacial pace, symptoms tend to hide for months or even years. According to Cancer Research UK, they account for around 8 per cent of all brain tumours, with risk increasing significantly after the age of 65. In rare cases, they are linked to a genetic condition called neurofibromatosis, which often causes tumours on both sides of the brain.

<h3>Why Dizziness Deserves a Second Look</h3>Most of us treat dizziness like a mild inconvenience. You get up too fast, feel woozy for a second, then go about your day. Maybe you chalk it up to dehydration, skipping breakfast, or scrolling on your phone in bed for too long. But dizziness could be a sign of something more serious. 

For John, it was not just one woozy episode. It was a string of unsettling, spin-the-room moments that left him lying flat on his back, eyes squeezed shut, praying for the world to stop pirouetting. And while vertigo was the first suspect, his brain had other plans, like growing a tumour on his vestibulocochlear nerve.

That is the thing with dizziness: it is vague, common, and often misunderstood. It can signal anything from low blood pressure and ear infections to neurological conditions that need serious medical attention. But because it is so easy to dismiss and hard to describe without wildly gesturing, it often gets brushed under the rug until it insists on being noticed.

If you face dizziness, do not ignore it. Especially if the dizziness is intense, recurrent, or comes with sidekicks like hearing loss, balance issues, or ringing in your ears. 

Health Conditions A-Z

health

vestibular schwannoma

brain tumour symptoms

dizziness causes

vertigo misdiagnosis

benign brain tumour

signs of vestibular schwannoma

dizziness and hearing loss

inner ear tumour

brain mri scan

neurological symptoms

Could This New Alzheimer’s Drug Buy Patients Four More Good Years? Here Is What We Know

Not Just A Workout, Why Everyone’s Training For HYROX Now?

Health News

What Should Fitness Look Like For A 13-18 Year Old

Food For Diabetes: What Should A Diabetic Diet Contain

You Don’t Always Need Weights For Strength Training

Feel Sleepy After Lunches - Light And Healthy Office Lunches

Positive Thinking Practice – How Does It Help You?

MIND Diet – Is This A Healthy Diet Or Another Trend?

Yoga Prop Essentials To Improve Your Exercise Session

Should Potatoes Be The Part Of A Healthy Diet?

Best And Worst Foods To Lower Blood Pressure

Low-Impact Cardio Workouts You Should Try

10 Healthy Pasta Salad Dressing For Weight Loss

Breathing Exercise You Should Do To Relieve Stress

Headache vs. Migraine: Difference Explained In 60 Seconds

High Carb Foods That Are Actually Healthy

How Many Times Do You Need To Wash Your Face?

Hypothyroidism Diet – What To Eat And What You Should Avoid

Stretches To Relieve Leg Pain And Numbness After Sitting For Too Long

No-Cook Healthy Meals For Lazy Days At Home

Easy Breakfast Options To Try During Calorie Deficit

How To Stop Muscle Cramps Immediately

Why You Should Go For An Anti-Inflammatory Diet

Foods To Lower Cortisol Levels In Your Body

High-Fiber Dips You Can Make At Home For The Week

Weekend Warrior Exercises To Makeup For Stressful Week

Experiencing Headaches At Word? Natural Remedies To Try

Yoga Poses That Enhance Digestion

Health Benefits of Walking Backwards

No Eggs? Egg-Alternatives You Can Add To Your Diet

Savory And Smart Ways To Add Broccoli To Your Diet

Calorie Burning Habits That Can Help You Shed Extra Pounds

Yoga Poses That Can Help With Bloating

Fiber-Rich Oatmeal Dishes You Can Have For Breakfast

Signs You Must Visit A Doctor For Your Back Pain

Avocado Meal Prep Ideas To Increase Healthy Fat In Your Diet

Arm Exercises You Can Do At Home

Quick-Office Lunches That Can Keep You Full-Longer

How Increased Screen Time Affects Children's Health

Homemade Recipe To Make Protein-Rich Pancakes With Healthy Alternatives

Push-Up Variations You Can Do At Home

Common Mistakes Running Mistakes People Make

When 63-year-old John Starns slumped on a train station bench in Sevenoaks, drenched in sweat and struggling to stay upright, most passers-by assumed he was drunk. He looked wobbly, pale, and visibly disoriented. But what looked like an awkward case of public intoxication turned out to be something far more sinister: a brain tumour hiding behind symptoms commonly mistaken for vertigo. From “It’s Just Vertigo” to “You Have a Brain Tumour”Initially told he had vertigo, John tried to carry on with his life. But as the months passed, his dizziness became more intense and debilitating. At their worst, the episodes forced him to lie down, eyes shut, until the world stopped spinning. Still, no one suspected the real cause.Three months and one MRI scan later, John finally got the truth. He reportedly had a vestibular schwannoma, a rare, benign brain tumour sitting on the nerve that connects the brain to the inner ear. It was affecting his balance, hearing, and overall coordination, symptoms that, in hindsight, were never typical of garden-variety vertigo.What is Vestibular Schwannoma?Despite the intimidating name, a vestibular schwannoma is not cancerous. It develops slowly over time from Schwann cells, the fatty insulation on your nerves. In this case, the tumour formed on the vestibulocochlear nerve, which governs both hearing and balance.That is why the symptoms can masquerade as something much less serious. Dizziness or vertigoHearing loss in one earRinging or buzzing sounds (tinnitus)Poor sound localisationIn more advanced cases, numbness on one side of the faceBecause these tumours grow at a glacial pace, symptoms tend to hide for months or even years. According to Cancer Research UK, they account for around 8 per cent of all brain tumours, with risk increasing significantly after the age of 65. In rare cases, they are linked to a genetic condition called neurofibromatosis, which often causes tumours on both sides of the brain.Why Dizziness Deserves a Second LookMost of us treat dizziness like a mild inconvenience. You get up too fast, feel woozy for a second, then go about your day. Maybe you chalk it up to dehydration, skipping breakfast, or scrolling on your phone in bed for too long. But dizziness could be a sign of something more serious. For John, it was not just one woozy episode. It was a string of unsettling, spin-the-room moments that left him lying flat on his back, eyes squeezed shut, praying for the world to stop pirouetting. And while vertigo was the first suspect, his brain had other plans, like growing a tumour on his vestibulocochlear nerve.That is the thing with dizziness: it is vague, common, and often misunderstood. It can signal anything from low blood pressure and ear infections to neurological conditions that need serious medical attention. But because it is so easy to dismiss and hard to describe without wildly gesturing, it often gets brushed under the rug until it insists on being noticed.If you face dizziness, do not ignore it. Especially if the dizziness is intense, recurrent, or comes with sidekicks like hearing loss, balance issues, or ringing in your ears. 

dizzy spells misread as vertigo led to brain tumour diagnosis for 63-year-old

Fitness

Lifestyle Changes People Above 60 Should Make To Boost Brain Health

lifestyle changes people above 60 should make to boost brain health

Health & Wellness

4 Rare Heart Diseases That Are Becoming Common By Each Passing Day

4 rare heart diseases that are becoming common by each passing day

'It’s Not Too Late': Even After A Lung Cancer Diagnosis, This One Habit Change Can Save Your Life

'it’s not too late': even after a lung cancer diagnosis, this one habit change can save your life

We Can Predict Heart Attacks Before They Happen, So Why Are We Not Doing It?

we can predict heart attacks before they happen, so why are we not doing it?

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called <span>lecanemab</span>, hailed as a game-changer in the fight against <span>dementia</span>.

The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.

<h3>How It Works</h3>Alzheimer’s is known for its slow but relentless grip on memory and cognition, typically marked by the build-up of sticky proteins in the brain. Lecanemab targets tau, a protein that increases as the disease worsens.

In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.

Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.

<h3>A Slow Slide Instead of a Steep Drop</h3>

Typically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.

Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.

<h3>Why Early Treatment is Key</h3>The benefits weren’t evenly distributed. Patients who had less evidence of Alzheimer’s pathology, that is, fewer early changes in the brain, showed the most striking outcomes. In other words, the earlier you start treatment, the better your odds of preserving function.

This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.

<h3>Not a Cure, But a Clear Step Forward</h3>

Lecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.

Lecanemab isn’t the only drug showing promise. A similar treatment called <span>donanemab</span> was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.

That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.

The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before. 

lecanemab

dementia drug

cognitive decline

tau protein

donanemab

memory loss therapy

Alzheimer's Disease

alzheimers

mental health

Dementia

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called lecanemab, hailed as a game-changer in the fight against dementia.The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.How It WorksAlzheimer’s is known for its slow but relentless grip on memory and cognition, typically marked by the build-up of sticky proteins in the brain. Lecanemab targets tau, a protein that increases as the disease worsens.In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.A Slow Slide Instead of a Steep DropTypically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.Why Early Treatment is KeyThe benefits weren’t evenly distributed. Patients who had less evidence of Alzheimer’s pathology, that is, fewer early changes in the brain, showed the most striking outcomes. In other words, the earlier you start treatment, the better your odds of preserving function.This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.Not a Cure, But a Clear Step ForwardLecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.Other Contenders in the RingLecanemab isn’t the only drug showing promise. A similar treatment called donanemab was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before. 

could this new alzheimer’s drug buy patients four more good years? here is what we know

Ishita Roy

Top U.S. Medical Associations Ousted from CDC Vaccine Workgroups in Sudden Shake-Up

RFK Jr. Is Leaving Behind 'Rigorous Science', Say Ousted Vaccine Panel Members

rfk jr. is leaving behind 'rigorous science', say ousted vaccine panel members

CDC Data Flags Alarming Rise In Childhood Vaccine Exemptions, Here's Why Doctor's Are Worried

cdc data flags alarming rise in childhood vaccine exemptions, here's why doctor's are worried

What Makes Flu Season 2025 Different? Unique Symptoms Of Flu In 2025 And How Long The Infection Lasts

unique symptoms of flu in 2025 and how long the infection lasts

Cholera Scare Rises In West and Central Africa With 8,000 Children At Risk

cholera scare rises in west and central africa with 8,000 children at risk

In a controversial move that has rattled the U.S. medical community, federal health officials have severed ties with more than half a dozen major medical organizations from participating in government vaccine advisory workgroups. 

The decision, communicated via email on Thursday, disinvites top experts from these groups from contributing to the workgroups that support the Advisory Committee on Immunization Practices (ACIP), a key body that guides the nation’s vaccination policies.

Organizations affected include the American Medical Association (AMA), the American Academy of Pediatrics (AAP), the Infectious Diseases Society of America (IDSA), and several others, many of whom have historically played a critical role in shaping vaccine guidelines.

“This is deeply concerning and distressing,” said Dr. William Schaffner, a renowned vaccine expert from Vanderbilt University who has been involved with ACIP workgroups for decades. “Removing these organizations will likely create conflicting messages about vaccine guidance. Patients might hear one thing from the government and another from their personal doctors.”

<h4>Longstanding Collaboration Ends Abruptly</h4>

For years, the ACIP has relied on a structured system where experts from various medical and scientific fields evaluate vaccine data and help draft recommendations. These recommendations, once approved by the Centers for Disease Control and Prevention (<span>CDC</span>), often inform clinical practice and determine insurance coverage.

But according to an email obtained by Bloomberg and confirmed by federal officials on Friday, the medical organizations are now being sidelined on the grounds that they are “special interest groups” and are assumed to carry a “bias” due to the populations they serve.

Dr. Schaffner defended the former system, highlighting how professional organizations offered practical insights on how recommendations could be realistically implemented in clinical settings. Importantly, all members were subject to conflict-of-interest vetting, ensuring objective guidance, he added.

<h4>Health Secretary Kennedy’s Sweeping Changes</h4>

This latest shake-up follows an earlier, unprecedented move in June when U.S. Health Secretary Robert F. Kennedy Jr. abruptly dismissed the entire ACIP panel, accusing it of being too closely aligned with vaccine manufacturers. Kennedy, a former leader in the anti-vaccine movement, has since appointed several known vaccine skeptics to the new committee.

Among the organizations removed from the workgroup process are the American Academy of Family Physicians, American College of Physicians, American Geriatrics Society, American Osteopathic Association, National Medical Association, and the National Foundation for Infectious Diseases.

In a joint statement released Friday, the AMA and several of the disinvited organizations denounced the decision, calling it “irresponsible” and “dangerous to our nation’s health.” The statement warned that excluding their medical expertise “will further undermine public and clinician trust in vaccines.”

The groups urged the administration to reverse the decision, emphasizing the importance of transparency and collaboration in public health decision-making.

Several of the ousted organizations had previously criticized Kennedy’s overhaul of the ACIP. Last month, three of them joined a lawsuit challenging the government’s decision to halt COVID-19 vaccine recommendations for most children and pregnant women, a policy shift that has been widely criticized by public health experts.

Meanwhile, newly appointed ACIP member Retsef Levi, a professor of business management with no formal medical background, defended the administration's direction on social media. Levi wrote that future workgroups would “engage experts from an even broader set of disciplines,” and claimed that membership would be based on “merit &amp; expertise, not organizational affiliations with conflicts of interest.”

The Department of Health and Human Services (HHS) has not yet disclosed which experts will replace the disinvited members or when the new workgroups will begin operating.

health news USA

health news

us medical associations

cc vaccine groups

In a controversial move that has rattled the U.S. medical community, federal health officials have severed ties with more than half a dozen major medical organizations from participating in government vaccine advisory workgroups. The decision, communicated via email on Thursday, disinvites top experts from these groups from contributing to the workgroups that support the Advisory Committee on Immunization Practices (ACIP), a key body that guides the nation’s vaccination policies.Organizations affected include the American Medical Association (AMA), the American Academy of Pediatrics (AAP), the Infectious Diseases Society of America (IDSA), and several others, many of whom have historically played a critical role in shaping vaccine guidelines.“This is deeply concerning and distressing,” said Dr. William Schaffner, a renowned vaccine expert from Vanderbilt University who has been involved with ACIP workgroups for decades. “Removing these organizations will likely create conflicting messages about vaccine guidance. Patients might hear one thing from the government and another from their personal doctors.”Longstanding Collaboration Ends AbruptlyFor years, the ACIP has relied on a structured system where experts from various medical and scientific fields evaluate vaccine data and help draft recommendations. These recommendations, once approved by the Centers for Disease Control and Prevention (CDC), often inform clinical practice and determine insurance coverage.But according to an email obtained by Bloomberg and confirmed by federal officials on Friday, the medical organizations are now being sidelined on the grounds that they are “special interest groups” and are assumed to carry a “bias” due to the populations they serve.Dr. Schaffner defended the former system, highlighting how professional organizations offered practical insights on how recommendations could be realistically implemented in clinical settings. Importantly, all members were subject to conflict-of-interest vetting, ensuring objective guidance, he added.Health Secretary Kennedy’s Sweeping ChangesThis latest shake-up follows an earlier, unprecedented move in June when U.S. Health Secretary Robert F. Kennedy Jr. abruptly dismissed the entire ACIP panel, accusing it of being too closely aligned with vaccine manufacturers. Kennedy, a former leader in the anti-vaccine movement, has since appointed several known vaccine skeptics to the new committee.Among the organizations removed from the workgroup process are the American Academy of Family Physicians, American College of Physicians, American Geriatrics Society, American Osteopathic Association, National Medical Association, and the National Foundation for Infectious Diseases.In a joint statement released Friday, the AMA and several of the disinvited organizations denounced the decision, calling it “irresponsible” and “dangerous to our nation’s health.” The statement warned that excluding their medical expertise “will further undermine public and clinician trust in vaccines.”The groups urged the administration to reverse the decision, emphasizing the importance of transparency and collaboration in public health decision-making.Lawsuit and FalloutSeveral of the ousted organizations had previously criticized Kennedy’s overhaul of the ACIP. Last month, three of them joined a lawsuit challenging the government’s decision to halt COVID-19 vaccine recommendations for most children and pregnant women, a policy shift that has been widely criticized by public health experts.Meanwhile, newly appointed ACIP member Retsef Levi, a professor of business management with no formal medical background, defended the administration's direction on social media. Levi wrote that future workgroups would “engage experts from an even broader set of disciplines,” and claimed that membership would be based on “merit & expertise, not organizational affiliations with conflicts of interest.”The Department of Health and Human Services (HHS) has not yet disclosed which experts will replace the disinvited members or when the new workgroups will begin operating.

top u.s. medical associations ousted from cdc vaccine workgroups in sudden shake-up

US Weighs China Travel Warning As Chikungunya Cases Near 5,000: Report

With Nearly 5,000 Active Cases Of This Deadly Virus, CDC Considers Travel Warning For China

with nearly 5,000 active cases of this deadly virus, cdc considers travel warning for china

Legionnaires Outbreak: All That You Need To Know About The Disease That Killed 1 And Left 22 Sick In New York

legionnaires outbreak: all that you need to know about the disease that killed 1 and left 22 sick in new york

The United States Centers for Disease Control and Prevention (CDC) is assessing a potential travel notice for China following a sharp rise in cases of <span>chikungunya</span>, a mosquito-borne viral infection that has sparked public health alarms in southern China, as reported by the <em>Independent </em>and the <em>South China Morning Post</em>.

Nearly 5,200 infections have been reported in the Guangdong province since early July, with most of them concentrated in the city of Foshan. Health officials there have since escalated their emergency response to a level III alert, which signals a “relatively major” public health threat in China’s four-tier system.

While the CDC has not yet published a formal advisory, a spokesperson told The Independent that the agency is “aware of the reported chikungunya outbreak in Guangdong Province in China and is currently assessing the size and extent of the outbreak.”

Chikungunya is a viral infection transmitted by the bite of an infected Aedes mosquito, the same mosquito species responsible for dengue and Zika. Symptoms typically include sudden onset of fever and joint pain, but may also include headache, muscle pain, swelling, and rash.

Although most cases are mild and self-limiting, some infections can lead to prolonged joint pain or, in rare cases, long-term complications. Serious outcomes are more likely among those with pre-existing health conditions. There are no antiviral treatments available, so prevention, particularly mosquito control and bite avoidance, remains the primary approach.

Vaccines against chikungunya have recently become available and are recommended for travelers to high-risk areas, although they are not yet widely accessible.

According to local health authorities in Foshan, around 95% of reported cases have been mild, with patients recovering within a week. However, the outbreak’s rapid spread has raised concern among international health bodies.

The outbreak in China follows a global pattern of chikungunya resurgence. The World Health Organization (WHO) issued an alert last week warning of the risk of the virus repeating its global spread from two decades ago. Diana Rojas Alvarez, a medical officer with WHO, said that nearly 5.6 billion people across 119 countries live in areas where the virus could potentially spread.

Chikungunya was first identified in 1952 in Tanzania and has since been detected in more than 110 countries, including major outbreaks in India, Italy, and the Americas. The virus is not spread from person to person; instead, it is carried by mosquitoes that have fed on infected individuals and then pass it to others.

The concern is not just local: international travel plays a key role in how the virus crosses borders. Infected travelers returning to or visiting countries with mosquito populations capable of transmitting the virus can trigger new outbreaks.

<h4>China’s response: Mosquito control and surveillance</h4>

The first case in this outbreak was reported in Foshan’s Shunde district on July 8 and was believed to be imported. Since then, local and national health authorities have moved quickly to contain the spread.

Measures taken include the use of drones to detect rooftop water accumulation, the release of larva-eating fish into lakes, and widespread public awareness campaigns. Residents have been urged to eliminate standing water, install window screens, and wear protective clothing.

Hospitals in affected areas have increased bed capacity for confirmed cases and designated specialized treatment centres. Border controls have been stepped up in Hong Kong to prevent imported cases from mainland China, with expanded testing capabilities introduced at key entry points.

<h4>CDC travel warnings: What it means for travelers</h4>

The CDC’s travel health notices are used to inform travelers about global disease risks and provide precautionary guidelines. The warning system has four levels, ranging from “practice usual precautions” (Level 1) to “avoid all travel” (Level 4).

As of now, China has only a Level 1 travel health notice for measles. However, the CDC has issued Level 2 notices for chikungunya in several countries including Bolivia, Kenya, and Madagascar in recent months.

If the CDC decides to escalate China’s status, it would be a significant development, both in terms of travel planning and diplomatic perception.

<h4>US–China tension and public health</h4>

The potential issuance of a travel notice also comes against the backdrop of complex US–China relations. While the CDC’s move would be grounded in public health data, the optics of a travel warning could have broader implications.

On Thursday, Chinese foreign ministry spokesperson Guo Jiakun responded to the reports, saying that China is in communication with the WHO and “making every effort to ensure a safe environment for travelers.”

The WHO has not issued any travel restrictions related to the outbreak but continues to monitor the situation closely.

With mosquito-borne diseases on the rise globally, driven by climate change, urbanization, and increased mobility, health experts advise travelers to stay informed and take preventive measures.

“Mosquito control is key,” said an official from the Hong Kong Centre for Health Protection. “Simple actions like using insect repellent, sleeping under mosquito nets, and avoiding stagnant water can go a long way in preventing infection.”

As global health agencies monitor the chikungunya outbreak in China, travelers to affected areas should remain vigilant and stay updated with official advisories. Prevention remains the best protection in the face of a disease with no cure.

chikungunya  China

health news usa

Chikungunya

chikungunya US china

China US Travel chikungunya

The United States Centers for Disease Control and Prevention (CDC) is assessing a potential travel notice for China following a sharp rise in cases of chikungunya, a mosquito-borne viral infection that has sparked public health alarms in southern China, as reported by the Independent and the South China Morning Post.Nearly 5,200 infections have been reported in the Guangdong province since early July, with most of them concentrated in the city of Foshan. Health officials there have since escalated their emergency response to a level III alert, which signals a “relatively major” public health threat in China’s four-tier system.While the CDC has not yet published a formal advisory, a spokesperson told The Independent that the agency is “aware of the reported chikungunya outbreak in Guangdong Province in China and is currently assessing the size and extent of the outbreak.”What is chikungunya?Chikungunya is a viral infection transmitted by the bite of an infected Aedes mosquito, the same mosquito species responsible for dengue and Zika. Symptoms typically include sudden onset of fever and joint pain, but may also include headache, muscle pain, swelling, and rash.Although most cases are mild and self-limiting, some infections can lead to prolonged joint pain or, in rare cases, long-term complications. Serious outcomes are more likely among those with pre-existing health conditions. There are no antiviral treatments available, so prevention, particularly mosquito control and bite avoidance, remains the primary approach.Vaccines against chikungunya have recently become available and are recommended for travelers to high-risk areas, although they are not yet widely accessible.According to local health authorities in Foshan, around 95% of reported cases have been mild, with patients recovering within a week. However, the outbreak’s rapid spread has raised concern among international health bodies.Global spread and WHO alertThe outbreak in China follows a global pattern of chikungunya resurgence. The World Health Organization (WHO) issued an alert last week warning of the risk of the virus repeating its global spread from two decades ago. Diana Rojas Alvarez, a medical officer with WHO, said that nearly 5.6 billion people across 119 countries live in areas where the virus could potentially spread.Chikungunya was first identified in 1952 in Tanzania and has since been detected in more than 110 countries, including major outbreaks in India, Italy, and the Americas. The virus is not spread from person to person; instead, it is carried by mosquitoes that have fed on infected individuals and then pass it to others.The concern is not just local: international travel plays a key role in how the virus crosses borders. Infected travelers returning to or visiting countries with mosquito populations capable of transmitting the virus can trigger new outbreaks.China’s response: Mosquito control and surveillanceThe first case in this outbreak was reported in Foshan’s Shunde district on July 8 and was believed to be imported. Since then, local and national health authorities have moved quickly to contain the spread.Measures taken include the use of drones to detect rooftop water accumulation, the release of larva-eating fish into lakes, and widespread public awareness campaigns. Residents have been urged to eliminate standing water, install window screens, and wear protective clothing.Hospitals in affected areas have increased bed capacity for confirmed cases and designated specialized treatment centres. Border controls have been stepped up in Hong Kong to prevent imported cases from mainland China, with expanded testing capabilities introduced at key entry points.CDC travel warnings: What it means for travelersThe CDC’s travel health notices are used to inform travelers about global disease risks and provide precautionary guidelines. The warning system has four levels, ranging from “practice usual precautions” (Level 1) to “avoid all travel” (Level 4).As of now, China has only a Level 1 travel health notice for measles. However, the CDC has issued Level 2 notices for chikungunya in several countries including Bolivia, Kenya, and Madagascar in recent months.If the CDC decides to escalate China’s status, it would be a significant development, both in terms of travel planning and diplomatic perception.US–China tension and public healthThe potential issuance of a travel notice also comes against the backdrop of complex US–China relations. While the CDC’s move would be grounded in public health data, the optics of a travel warning could have broader implications.On Thursday, Chinese foreign ministry spokesperson Guo Jiakun responded to the reports, saying that China is in communication with the WHO and “making every effort to ensure a safe environment for travelers.”The WHO has not issued any travel restrictions related to the outbreak but continues to monitor the situation closely.A word of caution for travelersWith mosquito-borne diseases on the rise globally, driven by climate change, urbanization, and increased mobility, health experts advise travelers to stay informed and take preventive measures.“Mosquito control is key,” said an official from the Hong Kong Centre for Health Protection. “Simple actions like using insect repellent, sleeping under mosquito nets, and avoiding stagnant water can go a long way in preventing infection.”As global health agencies monitor the chikungunya outbreak in China, travelers to affected areas should remain vigilant and stay updated with official advisories. Prevention remains the best protection in the face of a disease with no cure.

us weighs china travel warning as chikungunya cases near 5,000: report

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Dizzy Spells Misread as Vertigo Led to Brain Tumour Diagnosis for 63-Year-Old

Quick Stories

Could This New Alzheimer’s Drug Buy Patients Four More Good Years? Here Is What We Know

Top U.S. Medical Associations Ousted from CDC Vaccine Workgroups in Sudden Shake-Up

US Weighs China Travel Warning As Chikungunya Cases Near 5,000: Report

Health Conditions A-Z

Could This New Alzheimer’s Drug Buy Patients Four More Good Years? Here Is What We Know

Dizzy Spells Misread as Vertigo Led to Brain Tumour Diagnosis for 63-Year-Old

Not Just A Workout, Why Everyone’s Training For HYROX Now?